Logo image of NVCR

NOVOCURE LTD (NVCR) Stock Fundamental Analysis

NASDAQ:NVCR - Nasdaq - JE00BYSS4X48 - Common Stock - Currency: USD

22.09  +0.44 (+2.03%)

After market: 22.01 -0.08 (-0.36%)

Fundamental Rating

2

NVCR gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 190 industry peers in the Health Care Equipment & Supplies industry. NVCR may be in some trouble as it scores bad on both profitability and health. NVCR is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

NVCR had negative earnings in the past year.
In the past year NVCR has reported a negative cash flow from operations.
NVCR had negative earnings in 4 of the past 5 years.
NVCR had a positive operating cash flow in 4 of the past 5 years.
NVCR Yearly Net Income VS EBIT VS OCF VS FCFNVCR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -100M -200M

1.2 Ratios

NVCR has a Return On Assets (-12.26%) which is in line with its industry peers.
NVCR has a Return On Equity (-41.52%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -12.26%
ROE -41.52%
ROIC N/A
ROA(3y)-10.32%
ROA(5y)-6.11%
ROE(3y)-30.77%
ROE(5y)-18.29%
ROIC(3y)N/A
ROIC(5y)N/A
NVCR Yearly ROA, ROE, ROICNVCR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -20 -40 -60 -80

1.3 Margins

NVCR has a better Gross Margin (76.42%) than 88.83% of its industry peers.
In the last couple of years the Gross Margin of NVCR has grown nicely.
NVCR does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 76.42%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.57%
GM growth 5Y2.01%
NVCR Yearly Profit, Operating, Gross MarginsNVCR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -100 -200 -300

More info and screens

1

2. Health

2.1 Basic Checks

NVCR does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, NVCR has more shares outstanding
The number of shares outstanding for NVCR has been increased compared to 5 years ago.
NVCR has a worse debt/assets ratio than last year.
NVCR Yearly Shares OutstandingNVCR Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M
NVCR Yearly Total Debt VS Total AssetsNVCR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 200M 400M 600M 800M 1B

2.2 Solvency

Based on the Altman-Z score of 0.79, we must say that NVCR is in the distress zone and has some risk of bankruptcy.
NVCR has a Altman-Z score (0.79) which is in line with its industry peers.
NVCR has a Debt/Equity ratio of 1.81. This is a high value indicating a heavy dependency on external financing.
NVCR's Debt to Equity ratio of 1.81 is on the low side compared to the rest of the industry. NVCR is outperformed by 84.57% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.81
Debt/FCF N/A
Altman-Z 0.79
ROIC/WACCN/A
WACC7.82%
NVCR Yearly LT Debt VS Equity VS FCFNVCR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 200M 400M

2.3 Liquidity

A Current Ratio of 1.49 indicates that NVCR should not have too much problems paying its short term obligations.
Looking at the Current ratio, with a value of 1.49, NVCR is doing worse than 76.60% of the companies in the same industry.
A Quick Ratio of 1.44 indicates that NVCR should not have too much problems paying its short term obligations.
Looking at the Quick ratio, with a value of 1.44, NVCR is doing worse than 61.17% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.49
Quick Ratio 1.44
NVCR Yearly Current Assets VS Current LiabilitesNVCR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 200M 400M 600M 800M 1B

More info and screens

5

3. Growth

3.1 Past

NVCR shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 24.73%, which is quite impressive.
The Revenue has grown by 14.63% in the past year. This is quite good.
NVCR shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 15.47% yearly.
EPS 1Y (TTM)24.73%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%39.13%
Revenue 1Y (TTM)14.63%
Revenue growth 3Y1%
Revenue growth 5Y15.47%
Sales Q2Q%21.81%

3.2 Future

The Earnings Per Share is expected to grow by 8.64% on average over the next years. This is quite good.
The Revenue is expected to grow by 15.20% on average over the next years. This is quite good.
EPS Next Y32.92%
EPS Next 2Y7.91%
EPS Next 3Y5.57%
EPS Next 5Y8.64%
Revenue Next Year18.18%
Revenue Next 2Y10.24%
Revenue Next 3Y10.21%
Revenue Next 5Y15.2%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
NVCR Yearly Revenue VS EstimatesNVCR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 500M 1B 1.5B
NVCR Yearly EPS VS EstimatesNVCR Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 1 -1 2 -2

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for NVCR. In the last year negative earnings were reported.
Also next year NVCR is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NVCR Price Earnings VS Forward Price EarningsNVCR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NVCR Per share dataNVCR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y7.91%
EPS Next 3Y5.57%

More info and screens

0

5. Dividend

5.1 Amount

NVCR does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NOVOCURE LTD

NASDAQ:NVCR (2/21/2025, 8:00:01 PM)

After market: 22.01 -0.08 (-0.36%)

22.09

+0.44 (+2.03%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)10-30 2024-10-30/bmo
Earnings (Next)02-27 2025-02-27/bmo
Inst Owners86.66%
Inst Owner Change-0.43%
Ins Owners2.28%
Ins Owner Change0.1%
Market Cap2.39B
Analysts80
Price Target37.45 (69.53%)
Short Float %5.1%
Short Ratio4.75
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)21.93%
Min EPS beat(2)17.78%
Max EPS beat(2)26.08%
EPS beat(4)4
Avg EPS beat(4)18.94%
Min EPS beat(4)15.39%
Max EPS beat(4)26.08%
EPS beat(8)5
Avg EPS beat(8)2.11%
EPS beat(12)7
Avg EPS beat(12)-7.99%
EPS beat(16)7
Avg EPS beat(16)-136.07%
Revenue beat(2)2
Avg Revenue beat(2)7.08%
Min Revenue beat(2)5.63%
Max Revenue beat(2)8.53%
Revenue beat(4)3
Avg Revenue beat(4)4.36%
Min Revenue beat(4)-0.02%
Max Revenue beat(4)8.53%
Revenue beat(8)3
Avg Revenue beat(8)0.76%
Revenue beat(12)5
Avg Revenue beat(12)0.25%
Revenue beat(16)5
Avg Revenue beat(16)-1.08%
PT rev (1m)4.9%
PT rev (3m)31.12%
EPS NQ rev (1m)2.78%
EPS NQ rev (3m)2.78%
EPS NY rev (1m)1.24%
EPS NY rev (3m)0.76%
Revenue NQ rev (1m)3.11%
Revenue NQ rev (3m)3.11%
Revenue NY rev (1m)0.7%
Revenue NY rev (3m)0.7%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 4.14
P/FCF N/A
P/OCF N/A
P/B 6.62
P/tB 6.62
EV/EBITDA N/A
EPS(TTM)-1.4
EYN/A
EPS(NY)-1.63
Fwd EYN/A
FCF(TTM)-0.72
FCFYN/A
OCF(TTM)-0.35
OCFYN/A
SpS5.34
BVpS3.33
TBVpS3.33
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -12.26%
ROE -41.52%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 76.42%
FCFM N/A
ROA(3y)-10.32%
ROA(5y)-6.11%
ROE(3y)-30.77%
ROE(5y)-18.29%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.57%
GM growth 5Y2.01%
F-Score5
Asset Turnover0.47
Health
Industry RankSector Rank
Debt/Equity 1.81
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 375.45%
Cap/Sales 7.05%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.49
Quick Ratio 1.44
Altman-Z 0.79
F-Score5
WACC7.82%
ROIC/WACCN/A
Cap/Depr(3y)227.98%
Cap/Depr(5y)194.31%
Cap/Sales(3y)4.6%
Cap/Sales(5y)3.96%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)24.73%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%39.13%
EPS Next Y32.92%
EPS Next 2Y7.91%
EPS Next 3Y5.57%
EPS Next 5Y8.64%
Revenue 1Y (TTM)14.63%
Revenue growth 3Y1%
Revenue growth 5Y15.47%
Sales Q2Q%21.81%
Revenue Next Year18.18%
Revenue Next 2Y10.24%
Revenue Next 3Y10.21%
Revenue Next 5Y15.2%
EBIT growth 1Y29.98%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year77.3%
EBIT Next 3Y19.88%
EBIT Next 5Y11.73%
FCF growth 1Y-496.8%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-176.62%
OCF growth 3YN/A
OCF growth 5YN/A